1 August 2024 - A federal court backed the Biden administration’s Medicare drug price negotiation program on Wednesday, the latest in a string of legal losses for the pharmaceutical industry.

The latest opinion against Danish drugmaker Novo Nordisk is notable because the company argued that CMS overstepped by combining several insulin products as a single drug for price talks.

Read Politico article